The Pharma Letter Podcast — Episode 16 — EQRx plots radical disruption on pricing

Simon Wentworth

22 July 2022

episode16_big

More on this story...

1 Year on, EQRx adds $500 million in Series B financing

11 January 2021

CStone up on deal with EQRx for two immune checkpoint Inhibitors

27 October 2020

Not so easy to go low with drug prices, EQRx accepts

11 November 2022

EQRx gets MAA for aumolertinib accepted by EMA

2 December 2022

Companies featured in this story

More ones to watch >

More Features in Biotechnology

Epitopea teams up with Genevant in $124 million deal

20 December 2024

Mixed results for GSK’s Zejula/Jemperli combo

20 December 2024

Regeneron advances anticoagulant antibody program

20 December 2024

Astellas partners with Sangamo on cutting-edge gene therapy

20 December 2024

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze